TNF‐α blocking agents have been associated with an increased risk of serious infections, malignancies, hypersensitivity reactions, reactivation of latent tuberculosis, reactivation of latent hepatitis B, neurological reactions including demyelinating disease, hematological reactions, and heart failure.20 The gene discussed is TNF; the disease is demyelinating disease.